Proceeds will provide education and outreach about clinical research participation to patients and their families in minority and under-served communities
The Center for Information and Study on Clinical Research Participation (CISCRP), a Boston-based nonprofit organization, will be hosting its Medical Heroes Appreciation 5K Run & Walk in conjunction with the Drug Information Association (DIA) at the DIA 2019 Global Annual Meeting on June 24, in San Diego. The annual 5K salutes the millions of “Medical Heroes” who have given the gift of participating in clinical trials.
While CISCRP now hosts many such events across the country and virtually, the organization first conceived the idea for the Medical Heroes Appreciation 5K in October 2013. The DIA quickly stepped up, and at their Global Meeting in June 2014, became the first entity to host the event. Since then, thousands of runners and walkers have taken part in Med Hero events to show their support and appreciation.
“We understand the importance of clinical research volunteers and are proud to support CISCRP’s mission during the DIA 2019 Global Annual Meeting in San Diego. We know that so many of our attendees look forward to this early morning 5K, and it is our hope that DIA 2019 attendees will continue to participate in this event to honor Medical Heroes and raise awareness for clinical research,” says Sudip S. Parikh, PhD, Senior Vice President and Managing Director, DIA Americas.
Hundreds of attendees from DIA 2019 are expected to participate, along with members of the local San Diego public. CISCRP also accepts “virtual runners and walkers,” who are unable to attend in person. These participants register online and then run or walk in a location of their choosing.
In addition to the trek around the harborside course, CISCRP is providing educational health resources and a free breakfast. The event is greatly made possible with Olympiad-Level Sponsorship by WCG.
“We are tremendously thankful for WCG’s contribution to making our Med Hero Appreciation 5K possible,” says Ellyn Getz, Associate Director, Development & Community Engagement at CISCRP. “WCG has helped us in the past and continues to be a strong supporter of improving clinical research literacy and celebrating those who participate in clinical trials.”
Says Donald A. Deieso, Ph.D., Executive Chairman and Chief Executive Officer of WCG, “Without the many volunteers who take part in clinical trials, we would not have the life-saving medicines we have today. CISCRP’s Med Hero 5K affords us the opportunity to recognize and celebrate their extraordinary contribution to the future of human health.”
CISCRP’s Medical Heroes Appreciation 5K will be held on Monday, June 24, 6:30 a.m. to 7:30 a.m. To register, https://medhero5ksd19.eventbrite.com/?aff=actenewsletter
For additional information, go to www.ciscrp.org, email medheroevents@ciscrp.org
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.